National Joint Procurement Office Announces 11th Round VBP, AstraZeneca Dapagliflozin Leads Demand
On October 11, 2025, the National Joint Procurement Office (NJPO) released the full company list for...
Maxvax Biotech Secures NMPA Acceptance for Its Recombinant Herpes Zoster Vaccine
Maxvax Biotech announced today that the China National Medical Products Administration (NMPA) has accepted the...
Shandong Buchang Names Goodfellow as Exclusive Philippine Distributor for Efparepoetin Alfa to Treat CKD Anemia
Shandong Shandong Buchang Names Goodfellow as Exclusive Philippine Distributor for Efparepoetin Alfa to Treat CKD Anemia Co., Ltd....
Zhaoke Ophthalmology Secures Exclusive Indonesian Distribution Deal for NVK002, a Novel Atropine‑Based Myopia Treatment
Zhaoke Ophthalmology Limited (HKG: 6622), a leading China‑based ocular therapeutics company, announced today that it...
CSPC Pharmaceutical Group Announces NMPA Acceptance of Efmedaglutide Alfa Injection for Long‑Term Weight Management
CSPC Pharmaceutical Group Limited (HKG: 1093) today announced that the National Medical Products Administration (NMPA)...
UCB Biosciences Receives NMPA Marketing Authorization for Zilucoplan (Zilbrysq) in Adult Generalized Myasthenia Gravis
UCB S.A. (EBR: UCB), a global biopharmaceutical company, announced today that the National Medical Products...
Mabwell Bioscience Receives NMPA IND Approval for 7MW4911 CDH17‑Targeting ADC in Advanced Solid Tumors
Mabwell Bioscience (SHA: 688062) announced today that the National Medical Products Administration (NMPA) has granted...
GSK Receives China NMPA Approval for Shingrix in Immunocompromised Adults
GlaxoSmithKline (NYSE: GSK) announced today that the Chinese National Medical Products Administration (NMPA) has granted approval...
Arcutis Biotherapeutics Receives FDA Approval for ZORYVE (Roflumilast) Cream in Children 2‑5 Years with Atopic Dermatitis
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), the U.S. partner of Huadong Medicine Co., Ltd. (SHE: 000963), announced today that...
BeOne Medicines Receives FDA Breakthrough Therapy Designation for Sonrotoclax in Relapsed Mantle Cell Lymphoma
BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that the U.S. Food...
ReviR Therapeutics Secures FDA Orphan Drug Designation for RTX‑117, Targeting Charcot‑Marie‑Tooth Disease
ReviR Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan...
Everest Medicines Commences Global Phase I Trial of Universal mRNA Cancer Vaccine EVM14
Everest Medicines Limited (HKG: 1952) announced today that the first patient has been successfully dosed...
Boehringer Ingelheim Launches Trajenta Production in Zhangjiang, China
Boehringer Ingelheim (BI) announced today the official start‑up of its local manufacturing plan for the diabetes...
Amoytop Biotech Secures NMPA Approval for Pegbinterferon Combination Therapy in Chronic Hepatitis B
Amoytop Biotech Co. Ltd. (SHA: 688278) announced today that the National Medical Products Administration (NMPA)...
Sihuan Pharma Invests in Swiss Aesthetic Tech Company Suisselle, Secures Permanent Exclusive Distribution of CELLBOOSTER in China
Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced today that it has completed an equity...
Sino Biopharma Subsidiary Secures Breakthrough Therapy Designation for TQB2102 ADC Targeting HER2‑Positive Colorectal Cancer
Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a wholly‑owned subsidiary of China‑listed Sino Biopharmaceutical Ltd....
Everest Medicines Receives NMPA Approval for Universal Oncology Vaccine EVM14
Everest Medicines Limited (HKG: 1952) announced today that the National Medical Products Administration (NMPA) has...
Sichuan Kelun‑Biotech Wins NMPA Approval for Sacituzumab‑Tirumotecan in EGFR‑Mutant Lung Cancer
China‑listed Sichuan Kelun‑Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced today that the National Medical Products...
Beihai Biotech Secures FDA IND Approval for First‑In‑Class Peptide‑Drug Conjugate BH1621
China‑based Zhuhai Beihai Biotech Co., Ltd. announced today that its Category 1 innovative drug BH1621 has...
Sichuan Biokin’s SystImmune Receives $250 Million Triggered by Phase 2/3 Milestone in EGFR×HER3 ADC
China‑based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its wholly‑owned subsidiary SystImmune, Inc....